The tunnel-pocket hybrid ATX inhibitor GLPG1690 was the only inhibitor in its class to advance to a phase III clinical trial for IPF before being withdrawn, as it was believed to be ineffective at the terminal stage of the disease, which is characterized by higher concentrations of the ATX substrate, LPC. Here, ENPP2 is linked to idiopathic pulmonary fibrosis.